Acquisition Opportunity BioAgilytix San Diego acquired MicroConstants in 2021, signaling integration of GLP-compliant bioanalysis capabilities with a broader CRO platform. This creates a strategic cross-sell and bundle opportunity to offer end-to-end drug development services from discovery through preclinical and clinical phases.

Small to Mid Market MicroConstants operates with 51-200 employees and reported revenue under $1M, indicating a focus on niche, high-customization bioanalytical work. Target similarly sized biotech and specialty pharma firms seeking compliant bioanalysis, PK/metabolism studies, and biomarker analysis could yield high-value wins.

Specialized Capabilities Expertise includes regulated bioanalysis, LC/MS/MS, HPLC/UV, immunoassay, multiplex, and qPCR across small molecules and macromolecules. This positions for upsell when clients require comprehensive method development, validation, and sample analysis for complex drug programs.

Growth Through Biologics Recent branding and collaboration history with BioAgilytix emphasizes large molecule drug development support. Pursue opportunities with biologics-focused programs, including monoclonal antibodies and biomarkers, aligning with BioAgilytix’s extended capabilities.

Digital and Global Reach Past announcements show partnerships and regional presence with a global CRO parent. Leverage cross-promotional marketing, access to a broader client network, and joint proposals for multinational projects to expand deal size and geographic reach.